<DOC>
	<DOCNO>NCT01908257</DOCNO>
	<brief_summary>This drug-drug interaction study healthy volunteer evaluate potential pharmacokinetic ( PK ) effect ranitidine lesinurad .</brief_summary>
	<brief_title>Lesinurad Interaction Study With Ranitidine</brief_title>
	<detailed_description>This study evaluate potential effect ranitidine pharmacokinetics lesinurad . An early study demonstrate effect lesinurad PK presence calcium-containing magnesium- aluminum-containing antacid . The current study ass whether raise gastric pH , without presence cation , affect lesinurad PK PD fast state . If impact see , optional second cohort conduct fed state .</detailed_description>
	<mesh_term>Ranitidine</mesh_term>
	<mesh_term>Ranitidine bismuth citrate</mesh_term>
	<mesh_term>Lesinurad</mesh_term>
	<criteria>body weight ≥ 50 kg ( 110 lb ) body mass index ≥ 18 ≤ 30 kg/m2 . Screening sUA value ≤ 7.0 mg/dL . free clinically significant disease require physician 's care and/or would interfere study evaluation procedure . Subject clinically relevant abnormalties vital sign , ECG , physical examination safety laboratory value per Investigator 's judgment . history clinical manifestation significant metabolic , hematological , pulmonary , cardiovascular , gastrointestinal , neurologic , hepatic renal , urological , psychiatric disorder . history suspicion kidney stone . undergone major surgery within 3 month prior Day 1. donate blood experienced significant blood loss ( &gt; 450 mL ) within 12 week prior Day 1 give plasma donation within 4 week prior Screening visit . inadequate venous access unsuitable vein repeat venipuncture .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>